Trial Profile
A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLL13; GAIA
- 28 Mar 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 26 Mar 2024 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 24 Mar 2024 This trial has been completed in Finland (Global end date: 29 Feb 2024).